Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens.

Abstract

In a double-blind crossover trial, 200 mg feprazone 3-times a day was compared with 200 mg twice a day in the treatment of osteoarthritis. There was no difference in clinical efficacy or in adverse effects between the two dosage schedules. Because of its long elimination half-life (approximately 24 hours) it is suggested that feprazone should be given in twice daily dosage and is a simple and effective treatment for osteoarthritis.

• Authors: M R Laurent, D Berry, R Grahame
• Journal: Pharmatherapeutica (Pharmatherapeutica) Vol. 3 Issue 6 Pg. 393-7 ( 1983) ISSN: 0308-051X [Print] England
• PMID: 6353430 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Feprazone
• Phenylbutazone

Topics

• Aged
• Clinical Trials as Topic
• Double-Blind Method
• Drug Administration Schedule
• Feprazone (administration & dosage, adverse effects)
• Humans
• Middle Aged
• Osteoarthritis (diagnosis, drug therapy)
• Phenylbutazone (analogs & derivatives)